Health
newsGP – Novavax confirms efficacy against emerging coronavirus variants – RACGP
New data on Australia’s third vaccine candidate shows it is highly effective against most COVID-19 variants, which may prove crucial as production bottlenecks force…
News
New data on Australia’s third vaccine candidate shows it is highly effective against most COVID-19 variants, which may prove crucial as production bottlenecks force delays among other options.
Interim results Novavaxs phase 3 clinical trials show it has 95.6% efficacy against the main COVID strain.
The interim results from one arm of Novavax’s phase 3 clinical trials show it has 95.6% efficacy against the main coronavirus strain – and is almost as effective against the concerning UK variant,…
-
Business14 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business10 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General20 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts
-
Noosa News10 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred